To date Biovertis has secured funding from capital market sources of €21 million including investments by TVM Capital and Life Sciences Partners (LSP) as well as an atypical silent partnership provided by the Kapital & Wert Group, an Austrian corporate finance specialist.
In addition, the company has been awarded significant grants and loans from Austrian public institutions and the European Union supporting the scientific excellence of Biovertis' drug discovery approach.
To receive Biovertis' news releases, please subscribe to our news service.
